Related Experiment Videos
Octadentate catecholamide ligands for Pu(IV) based on linear or preorganized molecular backbones
P W Durbin1, B Kullgren, N Jeung
1Department of Chemistry, University of California, Berkeley, CA 94720, USA.
Human & Experimental Toxicology
|April 1, 1996
Summary
New octadentate ligands effectively reduced plutonium retention in mice. The penten backbone and MeTAM chelating unit show promise for actinide chelation therapy.
Area of Science:
- Medicinal Chemistry
- Radiochemistry
- Toxicology
Background:
- Plutonium (Pu) contamination poses significant health risks due to its radioactivity and tendency to deposit in tissues.
- Effective decorporation agents are crucial for mitigating Pu toxicity following internal exposure.
- Developing novel ligands with high affinity and selectivity for Pu is an ongoing challenge in radioprotective medicine.
Purpose of the Study:
- To synthesize and evaluate novel octadentate ligands for their efficacy in reducing plutonium retention in vivo.
- To compare the performance of ligands with different molecular backbones (spermine, DFO, penten) and chelating units (CAM, CAM(C), TAM).
- To identify the most effective ligand structure for enhancing plutonium excretion and reducing tissue deposition.
Main Methods:
- Synthesis of nine new octadentate ligands incorporating catecholamide, carboxycatecholamide, or terephthalamide chelating units on spermine, DFO, or penten backbones.
- Intravenous injection of 239Pu citrate into mice, followed by intraperitoneal or oral administration of ligands.
- Measurement of Pu retention in tissues and excretion levels at 24 hours post-administration.
Main Results:
- Soluble MeTAM ligands, particularly H(2,2)-MeTAM, significantly reduced whole-body Pu retention (27-28% of control) when administered via injection.
- Penten-based ligands demonstrated comparable or superior efficacy to existing agents like CaNa3-DTPA.
- H(2,2)-MeTAM showed superior efficacy in reducing liver Pu retention (16% of control) compared to CaNa3-DTPA (35% of control).
- Orally administered H(2,2)-MeTAM effectively reduced Pu retention (58% of control), outperforming CaNa3-DTPA (94% of control).
Conclusions:
- The penten backbone is a practical and suitable structural motif for developing effective octadentate ligands.
- The MeTAM chelating unit, especially when combined with the penten backbone in H(2,2)-MeTAM, is highly effective for in vivo plutonium chelation.
- H(2,2)-MeTAM represents a promising therapeutic candidate for enhancing plutonium excretion and mitigating its toxic effects.